What the regulator decided
Pakistan’s competition authority gave a green light for Citi Pharma Limited to buy every share of Pakheim International Pharma (Pvt.) Limited. The Competition Commission of Pakistan finished a Phase-I look under the Competition Act, 2010 and found no serious threat to rivalry. Islamabad-dated briefings place the decision on Thursday, 29 October.
Citi Pharma Limited (PSX: CPHL) is listed and makes finished medicines, medical chemicals, botanical goods, active pharmaceutical ingredients (APIs—the raw chemicals used in drugs), finished formulations and nutraceuticals. Pakheim is privately held and also makes and sells medicines. After completion, Pakheim is set to sit entirely under Citi Pharma’s ownership.
How the markets were drawn
For the review, the commission mapped five product spaces: antibiotic, anti-ulcer, painkiller, anti-allergic and anti-diabetic formulations. It found product overlap only in antibiotics, painkillers and anti-diabetic medicines, and judged Pakheim’s share too small to matter. No overlap was found in anti-ulcer or anti-allergic lines.
API supply check
Officials also checked whether Citi Pharma’s API production could lock out rivals if Pakheim bought those ingredients from its new parent. The assessment found Pakheim had not sourced any API from Citi Pharma in the past two years, so the possible vertical link did not raise competition concerns.
What the clearance means for rivalry
The commission said the deal would lift Citi Pharma’s share only negligibly in the overlapping segments. It would not raise entry barriers or stop existing rivals from competing. On that basis, CCP concluded the buyout would not substantially lessen competition or create or strengthen a dominant position in the markets it studied.
